Results 1 to 10 of about 21,238 (217)

Management of bone metastases in patients with breast cancer: review of bone-modifying therapy, emerging new agents, and future directions. [PDF]

Front Oncol
Bader G, Brown B, Davenport AP, Gatti-Mays M, Johnson KC, Lopetegui-Lia N, Quiroga D, Roy AM, Sardesai S, Stover D, Wesolowski R.   +10 more
europepmc   +1 more source

Efficacy and safety of denosumab, zoledronic acid and alendronate on bone mineral density and trabecular bone score in men with osteoporosis. [PDF]

Age Ageing
Zhou B, Zhang Y, Yu W, Sun L, Wang Y, Jiang Y, Wang O, Xing X, Xia W, Zhang J, Yan W, Li M.   +11 more
europepmc   +1 more source

Targeting RANKL-independent osteoclastogenesis overcomes denosumab resistance in models of ER+ breast cancer bone metastasis. [PDF]

J Clin Invest
Lin Q, Luo J, Duan Z, Luo J, Zhang W, Xia Y, Zeng Y, Fang X, Liang J, Chen J, Lin Q, Quan Y, Hu R, Liu H, Liu Q, Li J, Gong C.   +16 more
europepmc   +1 more source

Initial Denosumab Versus Sequential Bisphosphonate-to-Denosumab for Prevention of Skeletal-Related Events in Breast Cancer with Bone Metastases: A Retrospective, Single-Center Study. [PDF]

Cancers (Basel)
Zhao Y, Yu B, Feng W, Xie Y, Shi Y, Cao J.   +5 more
europepmc   +1 more source

Efficacy, pharmacodynamics, pharmacokinetics, safety, and immunogenicity of Bmab 1000 vs reference denosumab: 78-wk results from a randomized, double-blind, multicenter, parallel-arm Phase 3 trial (DEVOTE) in women with postmenopausal osteoporosis. [PDF]

JBMR Plus
Eastell R, Orwoll E, Cosman F, Plebanski R, Kumar K, Marwah A, Deodhar SS, Wolff-Holz E, Loganathan S.   +8 more
europepmc   +1 more source

The use of denosumab in rare bone diseases in adults: a systematic review from the ECTS Rare Bone Disease Action Group.

J Clin Endocrinol Metab
Bulaicon OO, van Haalen FM, Clunie GPR, Grasemann C, Lems WF, Makras P, Mortier G, Oheim R, Raimann A, Siggelkow H, Tabacco G, van der Wal RJP, de Witte PB, Appelman-Dijkstra NM.   +13 more
europepmc   +1 more source

Dual-target neoadjuvant therapy with denosumab and sunitinib for giant cell tumor of bone: a sarcoma center experience. [PDF]

J Bone Oncol
Mahdal M, Apostolopoulos V, Múdrý P, Neradil J, Kubíček M, Zoufalý D, Adámková D, Tomáš T.   +7 more
europepmc   +1 more source

Giant Cell Tumor of the Sacrum: A Narrative Review of Management Challenges and Modalities. [PDF]

Healthcare (Basel)
Alaseem A, Aldosari ZA, Alduraibi AA, Alzahrani RK, AlNahari AS, AlAqeel M, Alshaygy I.   +6 more
europepmc   +1 more source

Comparison of KN012, a denosumab biosimilar, versus reference denosumab in Chinese postmenopausal women with osteoporosis: efficacy, safety, and population pharmacokinetics in a 12-month phase III study. [PDF]

Bone Rep
Zhu X, Liu J, Mao Y, Li J, Shao F, Lin H.   +5 more
europepmc   +1 more source

Sequential Versus Step-Therapy Approaches for Osteoporosis Management in Orthopedic Subspecialties. [PDF]

Curr Osteoporos Rep
Salman SG, Phadke R, Burnett J, Walsh J.
europepmc   +1 more source